Publications

Strating E, Wassenaar E, Verhagen M, Rauwerdink P, van Schelven S, de Hingh I, Rinkes IB, Boerma D, Witkamp A, Lacle M, Fodde R, Volckmann R, Koster J, Stedingk K, Giesel F, de Roos R, Poot A, Bol G, Lam M, Elias S, Kranenburg O. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging. Volume 127 of Issue 1 British journal of cancer. 2022. PMID: 35296803

Magbanua MJM, Gumusay O, Kurzrock R, van 't Veer LJ, Rugo HS. Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Frontiers in oncology. 2022. PMID: 35372077

Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. PMID: 34965944

Wolf D, Barreras H, Copsel SN, Komanduri KV, Levy RB. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT. Transplantation and cellular therapy. 2022. PMID: 35302008

Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. The oncologist. 2022. PMID: 35274720

Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, Reznik E. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European urology focus. 2022. PMID: 35288096

Kwon DH, Cadena J, Nguyen S, Chan KHR, Soper B, Gryshuk AL, Hong JC, Ray P, Huang FW. COVID-19 outcomes in patients with cancer: Findings from the University of California health system database. Cancer medicine. 2022. PMID: 35261195

Sequeira N, Park KM, O'Sullivan P, Fee C, Foster-Barber A, McNamara M, Shinkai K, Vener M, Kim H, Cornett P, Alseidi A. Designing successful virtual residency interviews: a survey-based needs assessment of applicants across medical specialties. Global surgical education : journal of the Association for Surgical Education. 2022. PMID: 38624984

Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of the National Cancer Institute. 2022. PMID: 34636852

Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Frontiers in oncology. 2022. PMID: 35321431

Miller J, Vijayaraghavan M. Tobacco Industry Efforts to Respond to Smoke-Free Policies in Multi-Unit Housing: An Evaluation of Tobacco Industry Documents. International journal of environmental research and public health. 2022. PMID: 35270744

Logan AC. SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. Clinical lymphoma, myeloma & leukemia. 2022. PMID: 35410757

Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdominal radiology (New York). 2022. PMID: 35244755

Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL. Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. Journal of geriatric oncology. 2022. PMID: 35256304

Banerjee R, Huang CY, Dunn L, Knoche J, Ryan C, Brassil K, Jackson L, Patel D, Lo M, Arora S, Wong SW, Wolf J, Martin Iii T, Dhruva A, Shah N. Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. JMIR formative research. 2022. PMID: 35039279

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation and cellular therapy. 2022. PMID: 35247612

Vaughan H, Rugo HS, Haemel A. Risk-Based Screening for Cancer in Patients With Dermatomyositis: Toward a More Individualized Approach. JAMA dermatology. 2022. PMID: 35107570

Bernabe-Ramirez C, Velazquez AI, Olazagasti C, Decat Bergerot C, Bergerot PG, Corona Cruz J, Riano I, Adaniel C, Ramirez F, Anampa J, Cajina C, Mena E, Gracia E, Menendez A, Idrovo H, Bezares R, Castillo Fernandez OO, Duque L, Corrales-Rodríguez L, Ramos G, Kihn-Alarcón AJ, Schlam I, Bruno X, Umanzor G, Castro JL, Losco F, Ubillos L, Richardet E, Soto-Perez-de-Celis E, Duma N, HOLA COVID-19 Study Group. HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America. JCO global oncology. 2022. PMID: 35245084

Shashikumar SA, Waken RJ, Aggarwal R, Wadhera RK, Joynt Maddox KE. Three-Year Impact Of Stratification In The Medicare Hospital Readmissions Reduction Program. Health affairs (Project Hope). 2022. PMID: 35254934

Seshadri M, Crane GM, Gergis U. Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Hematology/oncology and stem cell therapy. 2022. PMID: 32413419